Clonal Population of Flucytosine-Resistant Candida tropicalis from Blood Cultures, Paris, France
Emerging Infectious Diseases, 2008 Candida tropicalis is a diploid ascomycetes yeast responsible for 4%–24% of candidemia. Resistance to flucytosine is rarely described for this species but was observed for 45 (35%) of 130 C.
Marie Desnos-Ollivier +8 more
doaj +2 more sources
Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal. [PDF]
, 2013 Current, widely accepted guidelines for the management of HIV-associated cryptococcal meningoencephalitis (CM) recommend amphotericin B combined with flucytosine (5-FC) for ≥2 weeks as the initial induction treatment of choice.
A. Loyse +9 more
core +1 more source
Wellcome Open Research, 2022 Introduction: Access to and the cost of induction treatment for cryptococcal meningitis (CM) is rapidly changing. The newly-announced price for flucytosine ($0.75 per 500 mg pill) and possibly lower prices for liposomal amphotericin B (AmB-L) create ...
Amir Shroufi +8 more
doaj +1 more source
A Prospective Longitudinal Study of the Clinical Outcomes from Cryptococcal Meningitis following Treatment Induction with 800 mg Oral Fluconazole in Blantyre, Malawi [PDF]
, 2013 Introduction: Cryptococcal meningitis is the most common neurological infection in HIV infected patients in Sub Saharan Africa, where gold standard treatment with intravenous amphotericin B and 5 flucytosine is often unavailable or difficult to ...
Mavuto Mukaka +50 more
core +1 more source
Case Reports in Critical Care, 2015 Purpose. A case report evaluating flucytosine dosing in a critically ill patient receiving continuous renal replacement therapy. Summary. This case report outlines an 81-year-old male who was receiving continuous venovenous hemofiltration (CVVH) for ...
Megan E. Kunka +3 more
doaj +1 more source
Prediction and experimental validation of solid solutions and isopolymorphs of cytosine/5-flucytosine [PDF]
, 2017 A computational search for polymorphs of cytosine, 5-flucytosine and a 1 : 1 mixture of the two substances not only rationalised the preferred packing arrangements but also enabled the finding and characterisation of cytosine/5-flucytosine solid ...
Braun, D. E. +3 more
core +1 more source
New Horizons in Antifungal Therapy
Journal of Fungi, 2016 Recent investigations have yielded both profound insights into the mechanisms required by pathogenic fungi for virulence within the human host, as well as novel potential targets for antifungal therapeutics.
Kaila M. Pianalto, J. Andrew Alspaugh
doaj +1 more source
Metabolites, 2020 We reviewed the licensed antifungal drugs and summarized their mechanisms of action, pharmacological profiles, and susceptibility to specific fungi. Approved antimycotics inhibit 1,3-β-d-glucan synthase, lanosterol 14-α-demethylase, protein ...
Jiří Houšť +2 more
doaj +1 more source
Population pharmacokinetics and CSF penetration of flucytosine in adults with HIV-associated cryptococcal meningoencephalitis. [PDF]
, 2023 BACKGROUND: There are limited data describing clinical flucytosine pharmacokinetics (PK). The variability of flucytosine partitioning into the CNS is not known.
Gondwe, Ebbie +57 more
core +1 more source
A Comparison of Amphotericin B Alone and Combined with Flucytosine in the Treatment of Cryptoccal Meningitis [PDF]
, 1979 We compared amphotericin B therapy for cryptococcal meningitis with a newer regimen containing both amphotericin B and flucytosine. In 50 patients with 51 courses of therapy adherent to the protocol, 27 courses were with amphotericin B and 24 with the ...
McGee, Zell A., , M.D. +29 more
core +1 more source